Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation
1
Issued Date
2024-01-01
Resource Type
ISSN
00411345
eISSN
18732623
Scopus ID
2-s2.0-85185589923
Pubmed ID
38368130
Journal Title
Transplantation Proceedings
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transplantation Proceedings (2024)
Suggested Citation
Yanyiam P., Kantachuvesiri S., Thammanichanond D. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation. Transplantation Proceedings (2024). doi:10.1016/j.transproceed.2024.01.030 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/97406
Title
Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: HLA eplet mismatching is an alternative approach to assess the risk of developing de novo donor-specific antibodies (dnDSA) in kidney transplantation. This strategy may offer more precise risk stratification than conventional approaches. This study aimed to find the association between HLA eplet mismatches and dnDSA formation in Thai kidney transplant recipients. Methods: A retrospective cohort study of kidney transplant recipients transplanted between 2000 and 2021 at Ramathibodi Hospital was performed. Recipients with pretransplant panel reactive antibody >0% or without DSA testing post-transplant were excluded. One hundred fifty recipients were included in the final study. High-resolution HLA typing was imputed by the HaploStat application. HLA eplet mismatch analysis was conducted using HLAMatchmaker. The association between the number of eplet mismatches and the risk of dnDSA formation was assessed by Cox regression analysis. Results: Of 150 recipients, 43 were dnDSA-positive, and 107 were dnDSA-negative patients. Compared with the dnDSA-negative group, patients with class II dnDSA had significantly more HLA-DR/DQ antibody (Ab)-verified eplet mismatches (6 [IQR 4-8] vs 4 [IQR 1-7], P = .045). The receiver operating characteristics analysis showed that the HLA-DQ Ab-verified eplet mismatches ≥2 were the best predictive of HLA class II dnDSA development. The number of HLA-DQ Ab-verified eplet mismatches ≥2 had the highest hazard rate of HLA class II dnDSA occurrence (adjusted HR, 3.74; 95%CI, 1.24-11.24, P = .019). Conclusions: HLA-DQ Ab-verified eplet mismatches are significantly associated with class II dnDSA development. Our data supports the utility of HLA eplet mismatching for donor-recipient risk assessment.